Power Wheelchair Group 3 denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for power wheelchair group3 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Power Wheelchair (Group 3) as Non-Formulary

The term "non-formulary" is more commonly applied to pharmaceuticals, but UHC and other insurers also maintain preferred vendor networks and device-coverage tiers for durable medical equipment (DME). A non-formulary denial for a Group 3 power wheelchair usually means one of three things: (1) the specific device model has not been included in UHC's covered equipment list or preferred DME supplier network; (2) the supplying DME company is out-of-network; or (3) the device carries features that UHC covers only at a higher cost-sharing tier or under a specific rider. The plan's own DME coverage policy and supplier-network directory are the authoritative sources for determining exactly which devices and vendors are covered.

This denial is appealable, particularly if no in-network supplier can provide the medically necessary device, or if the specific features your physician prescribed are not available in a covered alternative.

## Your Federal Appeal Rights

Under ACA §2719, you may pursue independent external review after exhausting internal appeals. Under ERISA §503 (self-funded plans), you are entitled to a full-and-fair internal review. The external-review window is generally approximately four months from the denial notice. If the lack of the device poses an urgent clinical risk, request expedited review.

## Documentation to Gather

• UHC DME coverage policy and supplier directory: identify whether any in-network supplier can provide the prescribed device model or a covered equivalent.
• Medical necessity for specific model/features: if a covered alternative exists, your prescribing physician and ATP should document in writing why that alternative is clinically inadequate and why the prescribed device's specific features are individually necessary.
• "No adequate alternative" letter: if no in-network supplier stocks a device meeting your clinical needs, document outreach to at least two or three in-network suppliers confirming unavailability. This supports a network-inadequacy exception.
• Cost-sharing analysis: confirm whether UHC's plan documents allow out-of-network coverage at in-network rates when no adequate in-network option exists (a right under ACA continuity-of-care and network-adequacy rules in many states).

## Criteria-Mapping Structure

Address the non-formulary denial by documenting why a covered alternative is not a clinically equivalent substitute:

| UHC Preferred / Covered Device | Why It Does Not Meet Clinical Need | |---|---| | [In-network alternative, if any] | [Physician/ATP explanation of clinical inadequacy] | | [Feature absent in covered alternative] | [Chart documentation of why that feature is medically necessary] |

Pair this table with written evidence of network-adequacy outreach to make the strongest possible case for an exception to standard formulary/network rules.